Esther Kinning
Southern General Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Esther Kinning.
Journal of Medical Genetics | 2014
Morad Ansari; G Poke; Quentin Rv Ferry; Kathleen A. Williamson; R. B. Aldridge; Alison Meynert; Hemant Bengani; C Y Chan; Hülya Kayserili; Ş Avci; Hennekam Rcm.; Anne K. Lampe; Egbert J. W. Redeker; Tessa Homfray; Allyson Ross; M F Smeland; Sahar Mansour; Michael J. Parker; Jackie Cook; Miranda Splitt; Robert B. Fisher; Alan Fryer; Alex Magee; Andrew O.M. Wilkie; A. Barnicoat; Angela F. Brady; Nicola S. Cooper; Catherine Mercer; Charu Deshpande; Christopher Bennett
Background Cornelia de Lange syndrome (CdLS) is a multisystem disorder with distinctive facial appearance, intellectual disability and growth failure as prominent features. Most individuals with typical CdLS have de novo heterozygous loss-of-function mutations in NIPBL with mosaic individuals representing a significant proportion. Mutations in other cohesin components, SMC1A, SMC3, HDAC8 and RAD21 cause less typical CdLS. Methods We screened 163 affected individuals for coding region mutations in the known genes, 90 for genomic rearrangements, 19 for deep intronic variants in NIPBL and 5 had whole-exome sequencing. Results Pathogenic mutations [including mosaic changes] were identified in: NIPBL 46 [3] (28.2%); SMC1A 5 [1] (3.1%); SMC3 5 [1] (3.1%); HDAC8 6 [0] (3.6%) and RAD21 1 [0] (0.6%). One individual had a de novo 1.3 Mb deletion of 1p36.3. Another had a 520 kb duplication of 12q13.13 encompassing ESPL1, encoding separase, an enzyme that cleaves the cohesin ring. Three de novo mutations were identified in ANKRD11 demonstrating a phenotypic overlap with KBG syndrome. To estimate the number of undetected mosaic cases we used recursive partitioning to identify discriminating features in the NIPBL-positive subgroup. Filtering of the mutation-negative group on these features classified at least 18% as ‘NIPBL-like’. A computer composition of the average face of this NIPBL-like subgroup was also more typical in appearance than that of all others in the mutation-negative group supporting the existence of undetected mosaic cases. Conclusions Future diagnostic testing in ‘mutation-negative’ CdLS thus merits deeper sequencing of multiple DNA samples derived from different tissues.
American Journal of Medical Genetics Part A | 2013
Katrina Tatton-Brown; Anne Murray; Sandra Hanks; Jenny Douglas; Ruth Armstrong; Siddharth Banka; Lynne M. Bird; Carol L. Clericuzio; Valérie Cormier-Daire; Tom Cushing; Frances Flinter; Marie Line Jacquemont; Shelagh Joss; Esther Kinning; Sally Ann Lynch; Alex Magee; Vivienne McConnell; Ana Medeira; Keiichi Ozono; Michael A. Patton; Julia Rankin; Debbie Shears; Marleen Simon; Miranda Splitt; Volker Strenger; Kyra Stuurman; Clare Taylor; Hannah Titheradge; Lionel Van Maldergem; I. Karen Temple
Weaver syndrome, first described in 1974, is characterized by tall stature, a typical facial appearance, and variable intellectual disability. In 2011, mutations in the histone methyltransferase, EZH2, were shown to cause Weaver syndrome. To date, we have identified 48 individuals with EZH2 mutations. The mutations were primarily missense mutations occurring throughout the gene, with some clustering in the SET domain (12/48). Truncating mutations were uncommon (4/48) and only identified in the final exon, after the SET domain. Through analyses of clinical data and facial photographs of EZH2 mutation‐positive individuals, we have shown that the facial features can be subtle and the clinical diagnosis of Weaver syndrome is thus challenging, especially in older individuals. However, tall stature is very common, reported in >90% of affected individuals. Intellectual disability is also common, present in ∼80%, but is highly variable and frequently mild. Additional clinical features which may help in stratifying individuals to EZH2 mutation testing include camptodactyly, soft, doughy skin, umbilical hernia, and a low, hoarse cry. Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident. The identification of an EZH2 mutation can therefore provide an objective means of confirming a subtle presentation of Weaver syndrome and/or distinguishing Weaver and Sotos syndromes. As mutation testing becomes increasingly accessible and larger numbers of EZH2 mutation‐positive individuals are identified, knowledge of the clinical spectrum and prognostic implications of EZH2 mutations should improve.
Human Mutation | 2015
María Concepción Gil-Rodríguez; Matthew A. Deardorff; Morad Ansari; Christopher A. Tan; Ilaria Parenti; Carolina Baquero-Montoya; Lilian Bomme Ousager; Beatriz Puisac; María Hernández-Marcos; María Esperanza Teresa-Rodrigo; Íñigo Marcos-Alcalde; Jan Jaap Wesselink; Silvia Lusa-Bernal; Emilia K. Bijlsma; Diana Braunholz; Inés Bueno-Martínez; Dinah Clark; Nicola S. Cooper; Cynthia J. Curry; Richard Fisher; Alan Fryer; Jaya Ganesh; Cristina Gervasini; Gabriele Gillessen-Kaesbach; Yiran Guo; Hakon Hakonarson; Robert J. Hopkin; Maninder Kaur; Brendan J. Keating; Maria Kibæk
Cornelia de Lange syndrome (CdLS) is characterized by facial dysmorphism, growth failure, intellectual disability, limb malformations, and multiple organ involvement. Mutations in five genes, encoding subunits of the cohesin complex (SMC1A, SMC3, RAD21) and its regulators (NIPBL, HDAC8), account for at least 70% of patients with CdLS or CdLS‐like phenotypes. To date, only the clinical features from a single CdLS patient with SMC3 mutation has been published. Here, we report the efforts of an international research and clinical collaboration to provide clinical comparison of 16 patients with CdLS‐like features caused by mutations in SMC3. Modeling of the mutation effects on protein structure suggests a dominant‐negative effect on the multimeric cohesin complex. When compared with typical CdLS, many SMC3‐associated phenotypes are also characterized by postnatal microcephaly but with a less distinctive craniofacial appearance, a milder prenatal growth retardation that worsens in childhood, few congenital heart defects, and an absence of limb deficiencies. While most mutations are unique, two unrelated affected individuals shared the same mutation but presented with different phenotypes. This work confirms that de novo SMC3 mutations account for ∼1%–2% of CdLS‐like phenotypes.
American Journal of Medical Genetics Part A | 2015
Paulien A. Terhal; Rutger A.J. Nievelstein; Eva J. J. Verver; Vedat Topsakal; Paula van Dommelen; Kristien Hoornaert; Martine Le Merrer; Andreas Zankl; Marleen Simon; Sarah F. Smithson; Carlo Marcelis; Bronwyn Kerr; Jill Clayton-Smith; Esther Kinning; Sahar Mansour; Frances Elmslie; Linda Goodwin; Annemarie H. van der Hout; Hermine E. Veenstra-Knol; Johanna C. Herkert; Allan M. Lund; Raoul C. M. Hennekam; André Mégarbané; Melissa Lees; Louise C. Wilson; Alison Male; Jane Hurst; Yasemin Alanay; Goeran Anneren; Regina C. Betz
Type 2 collagen disorders encompass a diverse group of skeletal dysplasias that are commonly associated with orthopedic, ocular, and hearing problems. However, the frequency of many clinical features has never been determined. We retrospectively investigated the clinical, radiological, and genotypic data in a group of 93 patients with molecularly confirmed SEDC or a related disorder. The majority of the patients (80/93) had short stature, with radiological features of SEDC (n = 64), others having SEMD (n = 5), Kniest dysplasia (n = 7), spondyloperipheral dysplasia (n = 2), or Torrance‐like dysplasia (n = 2). The remaining 13 patients had normal stature with mild SED, Stickler‐like syndrome or multiple epiphyseal dysplasia. Over 50% of the patients had undergone orthopedic surgery, usually for scoliosis, femoral osteotomy or hip replacement. Odontoid hypoplasia was present in 56% (95% CI 38–74) and a correlation between odontoid hypoplasia and short stature was observed. Atlanto‐axial instability, was observed in 5 of the 18 patients (28%, 95% CI 10–54) in whom flexion‐extension films of the cervical spine were available; however, it was rarely accompanied by myelopathy. Myopia was found in 45% (95% CI 35–56), and retinal detachment had occurred in 12% (95% CI 6–21; median age 14 years; youngest age 3.5 years). Thirty‐two patients complained of hearing loss (37%, 95% CI 27–48) of whom 17 required hearing aids. The ophthalmological features and possibly also hearing loss are often relatively frequent and severe in patients with splicing mutations. Based on clinical findings, age at onset and genotype–phenotype correlations in this cohort, we propose guidelines for the management and follow‐up in this group of disorders.
American Journal of Medical Genetics Part C-seminars in Medical Genetics | 2012
Paulien A. Terhal; Paula van Dommelen; Martine Le Merrer; Andreas Zankl; Marleen Simon; Sarah F. Smithson; Carlo Marcelis; Bronwyn Kerr; Esther Kinning; Sahar Mansour; Raoul C. M. Hennekam; Annemarie H. van der Hout; Valérie Cormier-Daire; Allan M. Lund; Linda Goodwin; Andre Megarbane; Melissa Lees; Regina C. Betz; Edward S. Tobias; Paul Coucke; Geert Mortier
From data collected via a large international collaborative study, we have constructed a growth chart for patients with molecularly confirmed congenital spondylo‐epiphyseal dysplasia (SEDC) and other COL2A1 related dysplasias. The growth chart is based on longitudinal height measurements of 79 patients with glycine substitutions in the triple‐helical domain of COL2A1. In addition, measurements of 27 patients with other molecular defects, such as arginine to cysteine substitutions, splice mutations, and mutations in the C‐terminal propeptide have been plotted on the chart. Height of the patients progressively deviate from that of normal children: compared to normal WHO charts, the mean length/height is −2.6 SD at birth, −4.2 SD at 5 years, and −5.8 SD in adulthood. The mean adult height (male and female combined) of patients with glycine substitutions in the triple‐helical region is 138.2 cm but there is a large variation. Patients with glycine to cysteine substitutions tend to cluster within the upper part of the chart, while patients with glycine to serine or valine substitutions are situated between +1 SD and −1 SD. Patients with carboxy‐terminal glycine substitutions tend to be shorter than patients with amino‐terminal substitutions, while patients with splice mutations are relatively tall. However, there are exceptions and specific mutations can have a strong or a relatively mild negative effect on growth. The observation of significant difference in adult height between affected members of the same family indicates that height remains a multifactorial trait even in the presence of a mutation with a strong dominant effect.
The Journal of Clinical Endocrinology and Metabolism | 2015
Angela Lucas-Herald; Esther Kinning; Aritoshi Iida; Zheng Wang; Noriko Miyake; Shiro Ikegawa; Jane McNeilly; S. Faisal Ahmed
CONTEXT Ciliopathies are a group of rare conditions that present through a wide range of manifestations. Given the relative common occurrence of defects of the GH/IGF-I axis in children with short stature and growth retardation, the association between ciliopathies and these defects needs further attention. CASE Our patient is a boy who was born at term and noted to have early growth retardation and weight gain within the first 18 months of life. Biochemical tests demonstrated low IGF-I but a normal peak GH on stimulation and an adequate increase in IGF-I on administration of recombinant human growth hormone (rhGH). A magnetic resonance imaging scan revealed pituitary hypoplasia and an ectopic posterior pituitary. His growth responded well to rhGH therapy. Subsequently he also developed a retinopathy of his rods and cones, metaphyseal dysplasia, and hypertension with renal failure requiring renal replacement therapy. Whole-exome sequencing demonstrated compound heterozygous mutations of IFT172, thus consistent with a ciliopathy. CONCLUSIONS This is the first reported case of a child with a mutation in IFT172 who presented with growth retardation in early childhood and was initially managed as a case of functional GH deficiency that responded to rhGH therapy. This case highlights the importance of ciliary function in pituitary development and the link between early onset growth failure and ciliopathies.
American Journal of Human Genetics | 2017
Cara M. Skraban; Constance F. Wells; Preetha Markose; Megan T. Cho; Addie Nesbitt; P.Y. Billie Au; Amber Begtrup; John A. Bernat; Lynne M. Bird; Kajia Cao; Arjan P.M. de Brouwer; Elizabeth Denenberg; Ganka Douglas; Kristin McDonald Gibson; Katheryn Grand; Alice Goldenberg; A. Micheil Innes; Jane Juusola; Marlies Kempers; Esther Kinning; David Markie; Martina M. Owens; Katelyn Payne; Richard Person; Rolph Pfundt; Amber Stocco; Claire Turner; Nienke E. Verbeek; Laurence E. Walsh; Taylor C. Warner
We report 15 individuals with de novo pathogenic variants in WDR26. Eleven of the individuals carry loss-of-function mutations, and four harbor missense substitutions. These 15 individuals comprise ten females and five males, and all have intellectual disability with delayed speech, a history of febrile and/or non-febrile seizures, and a wide-based, spastic, and/or stiff-legged gait. These subjects share a set of common facial features that include a prominent maxilla and upper lip that readily reveal the upper gingiva, widely spaced teeth, and a broad nasal tip. Together, these features comprise a recognizable facial phenotype. We compared these features with those of chromosome 1q41q42 microdeletion syndrome, which typically contains WDR26, and noted that clinical features are consistent between the two subsets, suggesting that haploinsufficiency of WDR26 contributes to the pathology of 1q41q42 microdeletion syndrome. Consistent with this, WDR26 loss-of-function single-nucleotide mutations identified in these subjects lead to nonsense-mediated decay with subsequent reduction of RNA expression and protein levels. We derived a structural model of WDR26 and note that missense variants identified in these individuals localize to highly conserved residues of this WD-40-repeat-containing protein. Given that WDR26 mutations have been identified in ∼1 in 2,000 of subjects in our clinical cohorts and that WDR26 might be poorly annotated in exome variant-interpretation pipelines, we would anticipate that this disorder could be more common than currently appreciated.
American Journal of Medical Genetics Part A | 2018
Leonie A. Menke; Thatjana Gardeitchik; Peter Hammond; Ketil Heimdal; Gunnar Houge; Sophia B. Hufnagel; Jianling Ji; Stefan Johansson; Sarina G. Kant; Esther Kinning; Eyby Leon; Ruth Newbury-Ecob; Stefano Paolacci; Rolph Pfundt; Nicola Ragge; Tuula Rinne; Claudia Ruivenkamp; Sulagna C. Saitta; Yu Sun; Marco Tartaglia; Paulien Terhal; Anthony van Essen; Magnus Dehli Vigeland; Bing Xiao; Raoul C. M. Hennekam
In 2016, we described that missense variants in parts of exons 30 and 31 of CREBBP can cause a phenotype that differs from Rubinstein–Taybi syndrome (RSTS). Here we report on another 11 patients with variants in this region of CREBBP (between bp 5,128 and 5,614) and two with variants in the homologous region of EP300. None of the patients show characteristics typical for RSTS. The variants were detected by exome sequencing using a panel for intellectual disability in all but one individual, in whom Sanger sequencing was performed upon clinical recognition of the entity. The main characteristics of the patients are developmental delay (90%), autistic behavior (65%), short stature (42%), and microcephaly (43%). Medical problems include feeding problems (75%), vision (50%), and hearing (54%) impairments, recurrent upper airway infections (42%), and epilepsy (21%). Major malformations are less common except for cryptorchidism (46% of males), and cerebral anomalies (70%). Individuals with variants between bp 5,595 and 5,614 of CREBBP show a specific phenotype (ptosis, telecanthi, short and upslanted palpebral fissures, depressed nasal ridge, short nose, anteverted nares, short columella, and long philtrum). 3D face shape demonstrated resemblance to individuals with a duplication of 16p13.3 (the region that includes CREBBP), possibly indicating a gain of function. The other affected individuals show a less specific phenotype. We conclude that there is now more firm evidence that variants in these specific regions of CREBBP and EP300 result in a phenotype that differs from RSTS, and that this phenotype may be heterogeneous.
Journal of pediatric genetics | 2016
Esther Kinning; Martin McMillan; Sheila Shepherd; Miep H. Helfrich; Rob van't Hof; Christopher I. Adams; Heather Read; Daniel M. Wall; S. Faisal Ahmed
The purpose of this study was to investigate the association of a chromosome 4:20 imbalance with osteoporosis in three related children. Bone biochemistry, bone turnover markers, and dual-energy X-ray absorptiometry (DXA) scanning were performed in all three cases and bone biopsy and histomorphometry in one. The chromosome imbalance was delineated by array comparative genomic hybridization (aCGH) and analyzed for candidate genes. A potential candidate gene within the deleted region is caspase-3, previously linked to low bone mineral density (BMD) in heterozygous mice thus caspase-3 activity was measured in cases and controls. Routine bone biochemistry and markers of bone turnover did not reveal any abnormality. DXA showed reduced total and lumbar spine bone mineral content. aCGH showed an 8 megabase (Mb) deletion of terminal chromosome 4q incorporating a region previously linked to low BMD and a 15 Mb duplication of terminal chromosome 20p. Bone biopsy showed a high bone turnover state, trabecularisation of cortical bone and numerous small osteoclasts coupled with normal bone formation. Basal serum caspase-3 activity was lower in cases compared with controls. We conclude that the early-onset osteoporosis with low basal levels of caspase-3 and abnormal osteoclasts is a feature of this chromosomal translocation. Further investigation of the role of the deleted and duplicated genes and especially caspase-3 is required.
bioRxiv | 2018
Jenny Lord; Giuseppe Gallone; Patrick Short; Jeremy McRae; Holly Ironfield; Elizabeth H. Wynn; Sebastian S. Gerety; Liu He; Bronwyn Kerr; Diana Johnson; Emma McCann; Esther Kinning; Frances Flinter; I. Karen Temple; Jill Clayton-Smith; Meriel McEntagart; Sally Ann Lynch; Shelagh Joss; Sofia Douzgou; Tabib Dabir; Virginia Clowes; Vivienne McConnell; Wayne Lam; Caroline F. Wright; David Fitzpatrick; Helen V. Firth; Jeffrey C. Barrett
Mutations which perturb normal pre-mRNA splicing are significant contributors to human disease. We used exome sequencing data from 7,833 probands with developmental disorders (DD) and their unaffected parents, as well as >60,000 aggregated exomes from the Exome Aggregation Consortium, to investigate selection around the splice site, and quantify the contribution of splicing mutations to DDs. Patterns of purifying selection, a deficit of variants in highly constrained genes in healthy subjects and excess de novo mutations in patients highlighted particular positions within and around the consensus splice site of greater functional relevance. Using mutational burden analyses in this large cohort of proband-parent trios, we could estimate in an unbiased manner the relative contributions of mutations at canonical dinucleotides (73%) and flanking non-canonical positions (27%), and calculated the positive predictive value of pathogenicity for different classes of mutations. We identified 18 patients with likely diagnostic de novo mutations in dominant DD-associated genes at non-canonical positions in splice sites. We estimate 35-40% of pathogenic variants in non-canonical splice site positions are missing from public databases.Accurate and efficient pre-mRNA splicing is crucial for normal development and function, and mutations which perturb normal splicing patterns are significant contributors to human disease. We used exome sequencing data from 7,833 probands with developmental disorders (DD) and their unaffected parents to quantify the contribution of splicing mutations to DDs. Patterns of purifying selection, a deficit of variants in highly constrained genes in healthy subjects and excess de novo mutations in patients highlighted particular positions within and around the consensus splice site of greater disease relevance. Using mutational burden analyses in this large cohort of proband-parent trios, we could estimate in an unbiased manner the relative contributions of mutations at canonical dinucleotides (73%) and flanking non-canonical positions (27%), and calculated the positive predictive value of pathogenicity for different classes of mutations. We identified 18 likely diagnostic de novo mutations in dominant DD-associated genes at non-canonical positions in splice sites. We estimate 35-40% of pathogenic variants in non-canonical splice site positions are missing from public databases.